Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pharmactive Biotech Products S.L.U | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Previous research has shown the efficacy of CROCUVIS+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. The main objective of this study is to evaluate the efficacy of CROCUVIS® in computer vision syndrome, sleep and mood disorders in a sample of university students who use digital devices.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Saffron extract (Crocus sativus) | Experimental | Daily intake of one tablet for 42 days. |
|
| Placebo | Placebo Comparator | Daily intake of one tablet for 42 days. This tablet is organoleptically indistinguishable from the experimental tablet. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Saffron extract (Crocus sativus) | Dietary Supplement | Daily intake of one tablet for 42 days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline computer vision syndrome at 14, 28 and 42 days | Measured with the Computer Vision Syndrome Questionnaire (CVS-Q©). It evaluates the frequency and intensity with which 16 symptoms are perceived over the time of use of digital devices. The score ranges from 0 to 32; computer vision syndrome is considered ≥6. The higher score a subject gained, the worsen ocular condition he/she experienced. | 0 (baseline), 14, 28 and 42 days |
| Change from baseline sleep disorders at 14, 28 and 42 days | Measured with the Insomnia Severity Index (ISI). It evaluates 7 items. The score ranges from 0 to 28 (worst). Each item is evaluated on a 5-point Likert scale (from 0 to 4). The final score is obtained from the sum of the responses of all items; insomnia is considered ≥8. | 0 (baseline), 14, 28 and 42 days |
| Change from baseline mood at 14, 28 and 42 days | Measured with the Profile of Mood States (POMS). It evaluates 58 items that form 6 factors (tension, depression, anger, vigour, fatigue, and confusion). The score ranges from 68 to 300 (worst mood). Each item is evaluated with a 5-point Likert scale (from 0 to 4). The score of each factor is obtained from the sum of the responses of all the items that define it. Total Mood Disturbance = 100+ (Tension + Depression + Anger + Fatigue + Confusion) - Vigour | 0 (baseline), 14, 28 and 42 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline quality of life related to health at 42 days | Measured with Short Form-36 survey (SF-36). It evaluates 36 items that form 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health). The scores are weighted sums of the questions in each section. The score ranges from 0 to 100. Lower scores = more disability, higher scores = less disability. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Monocular corrected distance visual acuity >0.0 LogMAR.
Ocular pathology under treatment at the time of the study.
Previous ocular surgery that could affect the tear film or the ocular surface.
Ocular Surface Disease Index (OSDI) questionnaire score ≥13.
Previous diagnosis or history of dry eye syndrome and/or blepharitis.
Regular (daily) use of rigid or soft contact lenses ≥3 days a week.
Regular use of any ocular lubricant.
History of oral intake of dietary supplements, with or without herbal ingredients, intended to contribute, maintain or reduce the risk of suffering diseases related to visual function, mood or sleep within the four weeks before the study enrollment.
Systemic disease:
Current systemic treatment or in the last 3 months with drugs that may interfere with the results, for example:
Habitual smoker and/or alcohol drinker. More than 3 cigarettes per day and/or more than 3 Standard Drink Units (SDU) per week, including weekends. SDU is defined as the consumption of 10 ml of alcohol.
Regular job with rotating shifts including night shift in the last month (including weekends).
Pregnancy or breastfeeding (also excludes recent pregnancy within the last 3 months) and women planning to become pregnant.
Participation in another clinical trial in the last 3 months.
Take any type of dietary supplements with botanical components in the last month.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alicante | San Vicent del Raspeig | Alicante | 03690 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012893 | Sleep Wake Disorders |
| D019964 | Mood Disorders |
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Daily intake of one tablet for 42 days. |
|
| 0 (baseline) and 42 days |
| Satisfaction question | A single satisfaction question. Participants must respond by selecting a number from a Likert scale from 0 to 5. | Last visit (42 day) |
| D001523 | Mental Disorders |